The CEO and founder of Luxembourg medtech MyelinZ talks about the firm’s non‑invasive brain‑computer interface (BCI) software for remotely monitoring and rehabilitating neurological conditions.
How does your platform improve MS monitoring using AI and wearable sensors?
MyelinZ turns speech, movement, and brain signals—captured during mobile neuroscience-based games—into digital biomarkers. Our AI spots hidden patterns, offering continuous, home-based MS monitoring and personalised cognitive rehabilitation without the clinic queue.
How does your approach differ from traditional MS treatments?
We go beyond symptoms—combining active monitoring with personalised rehab. Patients play, listen, and train via our app and brain-sensing headphones, gaining insights and game-based recovery plans in minutes, anywhere.
How do you ensure GDPR compliance?
We encrypt and anonymise all data, putting users fully in control. Our patent-pending federated learning technology ensures privacy without compromise—compliance by design, not afterthought.
Can your AI-driven rehabilitation be adapted to other diseases?
Certainly. Our tech already extends to Parkinson’s, stroke, dementia, and early cognitive decline—any condition where brain, speech, or movement needs tracking, training, or a touch of hope.
What are Myelin-H’s next steps with clinical trials?
We’re mid-launch of a global, 400-participant trial across 8+ centres. Backed by top hospitals, it’s double-blind and UK/EU/US-led. Meanwhile, BodyMirror—our non-medical digital brain gym—hits the market in weeks.
This article was published in Silicon Luxembourg magazine.
